

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: 14184798				
CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)				
Palabras clave utilizadas		Anti - DLL3 monoclonal antibodies, DLL3 protein, DLL3 modulators, DELTA-LIKE 3, delta-like protein 3, Delta 3, cáncer treatment, Antibody Drug Conjugates (ADCs), Pyrrolobenzodiazepine (PBDs).		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: C07K 16/28 // 16/30 // 14/47, A61K 47/48, A61P 35/00.		
		CPC (Opcional):		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/Prese ntación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	No hay registros que puedan afectar la patentabilidad de la solicitud	-	-	-
EPO (31/01/2014)	WO2011/093097	04/08/2011	-	A
	Human DLL3 Antibody Monoclonal Mouse IgG2B Clone # 378703, Catalog Number: MAB4315 Author:R&D Systems. Publication data:R&D System catalog. URL:http://www.rndsystems.com/pdf/MAB4315.pdf.	05/05/2010	-	A
	Anti-Delta3, clone 1E7.2. Author:Millipore. Publication data:20080715 usa URL:http://www.millipore.com/catalogue/item/MABT189?cid=bios-a-antr-1012-1206.	15/07/2008	-	A
	US2003/180784	25/09/2003	-	A
USPTO	US4676980	30/06/1987	-	A
	US4816567	28/03/1989	-	
	US5112946	12/05/1992	-	
	US5122368	16/06/1992	-	
	US5223409	29/06/1993	-	
Patbase*	US2012328624	27/12/2012	-	A
	US2004259114	23/12/2004	-	
	US2011256157	20/10/2011	-	
Patent Lens	No hay secuencias de aminoácidos relevantes que afecten la patentabilidad de la solicitud	-	-	-
*** Categorías especiales de documentos citados:				

*** Categorías especiales de documentos citados:

“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.	“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.	

Literatura no patente (Science Direct)	-Chapman G <i>et al.</i>, "Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis". Hum Mol Genet. Mar. 1, 2011;20(5):905-16. PMID: 21147753. -Dunwoodie <i>et al.</i>, "Mouse DLL3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo." Development. Aug. 1997;124(16):3065-76. -Geffers I <i>et al.</i>, "Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo." J Cell Biol. Jul. 30, 2007; 178(3):465-76. PMID: 17664336. -Henke RM <i>et al.</i> "Ascl1 and Neurog2 form novel complexes and regulate Delta-like3 (DLL3) expression in the neural tube." Dev Biol. Apr. 15, 2009; 328(2):529-40 PMID:19389376. -Hoyne GF, <i>et al.</i>, "A cell autonomous role for the Notch ligand Delta-like 3 in alphabeta T-cell development." Immunol Cell Biol. Apr. 2011; 89(6):696-705. PMID: 21151194.
--	--

Fecha del reporte de búsqueda:	15/02/2017
--------------------------------	------------

Búsqueda en PatBase

TAC= (Antibod* AND DLL3) AND CPC = (C07K OR A61K)

TAC= (Antibod* AND (DLL3 OR Delta3)) AND CPC = (C07K OR A61K)

TAC= (Antibod* NEAR DLL3) AND CPC = (C07K OR A61K)

TAC= ((Antibod* AND DLL3) AND (Conjugate* NEAR Pyrrolbenzodiazepine)) CPC = (C07K OR A61K)

13) Family number: 49385487 (US2012328624A)

Similar • Translate • Full-text • Status • Citations

Title: [EN] ANTI-DLL3 ANTIBODY

Abstract: Source: US2012328624A [EN] It is intended to disclose an **antibody** which binds to **DLL3** protein. Preferably, the **antibody** of the present invention recognizes a region from amino acids 216 to 492 in human **DLL3** having the amino acid sequence as set forth in SEQ ID NO: 1. The present invention also provides a pharmaceutical composition, for example, an anticancer agent, comprising the **antibody** of the present invention as an active ingredient. The present invention further discloses a method for diagnosing cancer using the **antibody** of the present invention and a diagnostic drug for cancer comprising the **antibody** of the present invention.

Classifications: [Classification Explorer](#)

International (IPC 8-9): A61K39/395 A61K47/48 A61P35/00 C07K16/18 C07K16/28 C07K16/30 C12N15/02 C12Q1/02 C12Q1/68 G01N33/50 G01N33/574 G01N33/68 (Advanced/Invention); A61K39/00 (Advanced/Non-invention)

CPC: C07K16/3023 A61K2039/505 C07K2317/24 C07K2317/30 C07K2317/732 C07K2317/77 C07K2319/30 C12Q1/6886 C12Q2600/118 G01N33/574 G01N2333/4703 A61K47/48592

European: C07K16/30D C12Q1/68M6B G01N33/574 M07K317/240 M07K317/732 M07K317/770 M07K319/30 M12Q600/118 S01N33/47A1

US: 424/139.1 424/178.1 435/375 435/7.23 530/387.9 530/391.7

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
EP2530091 A1	20121205	EP20110736812	20110128	
EP2530091 A4	20130710	EP20110736812	20110128	
JP2011093097 A1	20130530	JP20110551775T	20110128	



Title: [EN] **DLL3** MODULATORS AND METHODS OF USE

Abstract: Source: US2014363455A [EN] Novel modulators, including **antibodies** and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

Classifications: [Classification Explorer](#)

International (ipc s-9): A61K31/407 A61K31/551 A61K31/5517 A61K39/395 A61K45/00 A61K47/42 A61K47/48 A61P11/00 A61P35/00 C07K C07K14/47 C07K16/00 C07K16/18 C07K16/28 C07K16/30 C07K16/46 C12N1/15 C12N1/19 C12N1/21 C12N15/00 C12N15/09 C12N15/13 C12N15/63 C12N5/10 C12P21/08 G01N33/53 G01N33/563 G01N33/574 G01N33/577 (Advanced/invention); A61K39/00 (Advanced/Non-invention); A61K A61P C07K (Subclass/invention)

CPC: A61K31/5517 A61K2039/505 C07K16/30 A61K47/48469 A61K47/48569 C07K2317/24 C07K2317/33 C07K2317/34 C07K2317/92 C07K2319/30 A61K47/48723 C07K2317/565 A61K39/3955 A61K47/48561 A61K47/48592 C07K16/3023 C07K2317/70 C07K2317/77 G01N33/57423 G01N33/57492 G01N2333/70596 C07K2317/21 C07K2317/31 C07K2317/35 C07K2317/55 C07K2317/54 C07K2317/622 C07K16/2809 C07K2317/76 A61K47/48715 C07K16/3069 C07K2317/73 C07K16/18 A61K47/48384 A61K47/48538 C07K16/28
US: 1/1 424/130.1 424/134.1 424/139.1 424/141.1 424/178.1 424/179.1 424/181.1 435/235.1 435/252.3 435/320.1 435/325 435/326 435/352 435/354 435/358 435/69.1 435/7.23 530/387.1 530/387.3 530/387.9 530/388.1 530/391.7 530/391.9 536/23.53

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
AU2013203459 AA	20130912	AU20130203459	20130222	
CA2865404 AA	20140822	CA20132865404	20130222	
CL2014002240 A1	20150515	CL20140002240	20140822	
CN104520324 A	20150415	CN201380010475	20130222	



Title: [EN] **PYRROLOBENZODIAZEPINES** AND **CONJUGATES** THEREOF

Abstract: Source: US2011256157A [EN] **Conjugates** and compounds for making **conjugates** which are PBD molecules linked via the N10 position are disclosed, along with the use of the **conjugates** for treating proliferative diseases, including cancer.

Classifications: [Classification Explorer](#)

International (IPC 8-9): A61K31/5517 A61K31/5517 A61K38/05 A61K39/395 A61K47/42 A61K47/48 A61P35/00 B65D85/84 C07D C07D487/02 C07D487/04 C07D519/00 C07K16/00 C07K16/18 C07K16/28 C07K16/30 C07K17/02 C07K5/062 C07K5/065 (Advanced/Invention);

A61P35/00 (Advanced/Non-invention);

A61K47/00 A61K47/48 A61P35/00 C07D487/00 C07D487/04 (Core/Invention);

A61K31/5517 A61P35/00 C07D487/04 (Core/Non-invention);

A61K A61P C07D (Subclass/Invention)

CPC: A61K47/48638 A61K47/48561 A61K47/48584 C07D487/04 C07D519/00

European: A61K47/48T4B28 A61K47/48T4B30B A61K47/48T4B30P C07D487/04 C07D519/00

US: 206/524.1 206/524.100S 424/178.1 424/181.1 424/181.100P 530/391.7 530/391.9 530/391.900S 540/496 540/496S 540/561

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
AU2011239507 AA	20111020	AU20110239507	20110415	☐
AU2011239507 BB	20150409	AU20110239507	20110415	☐

PatBase - US2011256157_A1

Patent Application Publication US 2011/0239507 A1 US 2011/0239507 A1





Figure 1a




Figure 1b